ADME Research Domain: Metabolism; Absorption; Excretion
Short Description
A stable HEK293 cell line expressing rat URAT1, designed for the preclinical assessment of uric acid transport and gout therapeutics.
Brand
Vesitra™
Development Stage
ADME
ADME Research Domain
Metabolism; Absorption; Excretion
Description
Designed to mirror the primary mechanism of uric acid reabsorption in the rat kidney, the Vesitra™ Rat URAT1 cell line provides a robust in vitro platform for evaluating the pharmacological efficacy and species-specific transport kinetics of novel uricosuric agents directly in a rodent background.
Features
1. Robust and specific cellular uptake of uric acid and related anionic substrates. 2. Rigorously calibrated against known clinical and preclinical URAT1 inhibitors. 3. Standardized HEK293 background allowing for seamless integration into existing high-throughput screening workflows.
Applications
Pharmacodynamic screening of gout drug candidates intended for rodent efficacy models; Evaluating species differences in renal uric acid handling and excretion.
Parental Cell Line
Human Embryonic Kidney 293 (HEK293)
Transfection
Stable Transfection
Transporter
rUrat1
Gene
Slc22a12
Typical Probe Substrate
Uric acid
Reference Inhibitor
Benzbromarone
Organism
Human
Strain Name
HEK293
Tissue
Embryonic Kidney
Background
Rat URAT1 (Slc22a12) expresses the rat ortholog of the crucial renal urate transporter. Because uric acid metabolism and transport differ significantly between rodents and humans, utilizing a species-matched in vitro model is critical when evaluating the efficacy and mechanism of action of novel uricosuric agents in preclinical rodent studies.